Detection and Clinical Value of BRAF Gene Mutation in Papillary Thyroid Carcinoma 

The purpose of this study is to investigate the mutation of BRAF gene in patients with papillary thy-roid carcinoma and analyze its clinical value. From January 2018 to March 2019, 813 patients in our hospital were select-ed for BRAF gene mutation detection. In terms of T3 index and T4 index, there was statistical difference between group 4 and group 3 (P<0.05); in terms of TSH index, there was statistical difference between group 1 and group 2 (P<0.05); in terms of TGAb and TPOAb indexes, there was statistical significance between each group (P<0.05); the negative and positive rates of central area transfer were lower than those of non-central area transfer (P<0.05); The incidences of nega-tive and positive BRAF gene in cervical metastasis were higher than those in non- cervical metastasis, and the incidences of negative and positive BRAF gene in cervical metastasis were higher than those in non-central metastasis (P<0.05). The results show that the mutation of BRAF V600E gene in papillary thyroid carcinoma is significantly related to TSH, TGAb and TPOAb, and the tumor is more likely to be invaded in BRAF V600E gene positive patients.